Pall Teams Up with RITT to Advance Transplantation Science
Pall Teams Up with RITT to Advance Transplantation Science
EAST HILLS, NY, July 12, 2007-Pall Corporation (NYSE:PLL) announced the establishment of a collaborative sponsorship agreement with the Research in Immune Tolerance in Transplantation (RITT) program at the Toronto General Hospital (University Health Network) located in Toronto, Canada.
The research and development, training, and education activities that are the focus of this collaboration will take place in the RITT Industrial BioDevelopment Laboratory (http://www.ibdl.ca), a state of the art facility for biotherapeutic and bioassay processing and development. The RITT program is funded jointly by the Canadian federal government (Canada Foundation for Innovation), the province of Ontario (Ontario Research Foundation), and the Toronto General Hospital. The RITT program is headed by Dr. Gary Levy, the director of the Multi-Organ Transplant Program (MOT) at the University Health Network, and one of the world leaders in both transplantation research and clinical practice. The MOT is Canada’s largest organ transplantation program and one of the largest in North America.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
